Orio Therapeutics, a Monthey (Valais)-based biotech company at the forefront of protein engineering for regenerative medicine, has completed its first funding round, securing CHF 500,000 from angel investors. The funds will propel the company’s upcoming plans, including preparations for its pre-clinical studies..

Orio Therapeutics是一家总部位于Monthey（Valais）的生物技术公司，位于再生医学蛋白质工程的前沿，已完成第一轮融资，从天使投资者那里获得了50万瑞士法郎。这些资金将推动公司即将实施的计划，包括临床前研究的准备工作。

Most protein-based therapeutics in regenerative medicine have limited success due to uncontrolled drug delivery, which can result in side effects and high costs. Based on its technology, Orio Therapeutics, based at the BioArk Technological Site in Monthey and in Monash University in Melbourne, Australia, is dedicated to unlocking the power of protein engineering and targeted drug delivery for the creation of next-generation regenerative medicines.

由于不受控制的药物递送，再生医学中大多数基于蛋白质的疗法的成功有限，这可能导致副作用和高成本。基于其技术，Orio Therapeutics位于Monthey的BioArk技术网站和澳大利亚墨尔本的莫纳什大学，致力于释放蛋白质工程和靶向药物输送的力量，以创造下一代再生药物。

Its technology modifies therapeutic proteins to improve delivery through controlled localization, for enhanced efficacy, reduced dosage and reduced side effects across various therapeutic areas. .

其技术通过控制定位来修饰治疗性蛋白质以改善递送，从而增强功效，减少剂量并减少各个治疗区域的副作用。

The current focus lies on the development of its lead program, a groundbreaking cardioprotective drug for patients with myocardial infarction, also known as heart attack. This novel therapy aims to prevent the extensive and often irreversible damage that commonly occurs following an acute myocardial infarction.

目前的重点是开发其lead计划，这是一种针对心肌梗塞（也称为心脏病发作）患者的开创性心脏保护药物。这种新疗法旨在预防急性心肌梗死后常见的广泛且通常不可逆的损伤。

Preparations for the pre-clinical studies are underway..

临床前研究的准备工作正在进行中。

Angel investors have invested half a million in the company, providing it with the required resources to advance its lead candidate into the next phase.  “We are deeply grateful for the confidence our investors have placed in our team and our cutting-edge approach,” said Dr. Ziad Julier, CEO of Orio Therapeutics.

天使投资者已向该公司投资50万美元，为其提供了所需资源，以推动其主要候选人进入下一阶段。Orio Therapeutics首席执行官Ziad Julier博士表示：“我们非常感谢投资者对我们的团队和前沿方法的信心。”

“Current treatments for heart attack patients typically fall short of preventing long-term complications. With this funding, we’re one step closer to providing a solution that truly addresses this significant unmet need.” (Press release/RAN) .

“目前对心脏病发作患者的治疗通常无法预防长期并发症。有了这笔资金，我们离提供真正解决这一重大未满足需求的解决方案又近了一步。”（新闻稿/RAN）。